Biomarkers: Unrealized potential in sports doping analysis

Bioanalysis

Volumn 1, Issue 6, 2009, Pages 1103-1118

  Teale, Phil ^a   Barton, Chris ^a   Driver, Philip M ^a   Kay, Richard G ^a  

^a Quotient Bioresearch Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ANIMAL; DOPING; GENE EXPRESSION PROFILING; HUMAN; METABOLOMICS; METHODOLOGY; PROTEOMICS; REVIEW; SUBSTANCE ABUSE;

ANIMALS; BIOLOGICAL MARKERS; DOPING IN SPORTS; GENE EXPRESSION PROFILING; HUMANS; METABOLOMICS; PROTEOMICS; SUBSTANCE ABUSE DETECTION;

EID: 79953317319     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.09.87     Document Type: Review

References (111)

1. Sjoqvist F, Garle M, Rane A. Use of doping agents, particularly steroids, in sports and society. Lancet 371(9627), 1872-1882 (2008).
2. Catlin DH, Fitch KD, Ljungqvist A. Medicine and science in the fight against doping in sport. J. Intern. Med. 264, 99-114 (2008).
3. Thevis M, Schänzer W. The anti-doping fight from the controller's view - prevention by means of future oriented analytics. Dtsch. Z. Sportmed. 60(3), 66-69 (2009).
4. Fitch KD. Androgenic-anabolic steroids and the Olympic Games. Asian. J. Androl. 10(3), 384-390 (2008).
5. Kicman AT. Pharmacology of anabolic steroids. Br. J. Pharmacol. 154(3), 502-521 (2008).
6. Bahrke MS, Yesalis CE. Abuse of anabolic androgenic steroids and related substances in sport and exercise. Pharmacol. 4, 614-620 (2004).
7. Thevis M, Kuuranne T, Geyer H, Schanzer W. Annual banned substance review: the prohibited list 2008 - analytical approaches in human sports drug testing. Drug Test. Analysis 1, 4-13 (2009).
8. Thevis M, Kohler M, Schänzer W. New drugs and methods of doping and manipulation. Drug Discov. Today 33(1-2), 59-66 (2008).
9. Thevis M, Schanzer W. Emerging drugs - Potential for misuse in sport and doping control detection strategies. Mini. Rev. Med. Chem. 7(5), 533-539 (2007).
10. Thevis M, Thomas A, Kohler M, Beuck S, Schanzer W. Emerging drugs: mechanism of action, MS and doping control analysis. J. Mass. Spectrom. 44(4), 442-460 (2009).
11. Thevis M, Schanzer W. MS in sports drug testing: Structure characterization and analytical assays. Mass Spectrom. Rev. 26(1), 79-107 (2007).
12. Catlin DH, Sekera MH, Ahrens BD, Starcevic B, Chang YC, Hatton CK. Tetrahydrogestrinone: discovery, synthesis, and detection in urine. Rapid Commun. Mass Spectrom. 18, 1245-1049 (2004).
13. Georgakopolus CG, Vonaparti A, Stamou M et al. Preventive doping control analysis: liquid and gas chromatography time-of-flight MS for detection of designer drugs. Rapid. Commun. Mass. Spectrom. 21(15), 2439-2446 (2007).
14. Thevis M, Schanzer W. Identification and characterization of peptides and proteins in doping control analysis. Curr. Proteomics 27(1), 35-50 (2008).
15. Thevis M, Thoma A, Schanzer W. Mass spectrometric determination of insulins and their degradation products in sports drug testing. Mass Spectrom. Rev. 27(1), 35-50 (2008).
16. Lasne F, Martin L, Crepin N, de Ceaurriz CJ. Detection of isoelectric profiles of erythropoietin in urine: differentiation of natural and administered recombinant hormones. Anal. Biochem. 311, 119-126 (2002).
17. Breidbach A, Catlin DH, Green GA, Tregub I, Truong H, Gorzek J. Detection of recombinant human erythropoietin in urine by isoelectric focusing. Clin. Chem. 49, 901-907 (2003).
18. Wells DJ. Gene doping: the hype and the reality. Br. J. Pharmacol. 154, 623-631 (2008).
19. Baoutina A, Alexander IE, Rasko JEJ, Emslie KR. Developing strategies for detection of gene doping. J. Gene M. 10, 3-20 (2008).
20. Harridge SD, Velloso CP. Gene doping. Essays Biochem. 44, 125-138 (2008).
21. Gatzidou E, Gatzidou G, Theocharis SE. Genetically transformed world records: a reality or in the sphere of fantasy? Med. Sci. Monit. 15, 41-47 (2009).
22. Azzazy HME, Mansour MMH, Christenson RH. Gene doping: of mice and men. Clin. Biochem. 42, 435-441 (2009).
23. Zolg JW, Langen H. How industry is approaching the search for new diagnostic markers and biomarkers. Mol. Cell Proteomics 3, 345-354 (2004).
24. Zhang X, Wei D, Yap Y, Li L, Guo S, Chen F. MS-based "omics" technologies in cancer diagnostics. Mass Spectrom. Rev. 26, 403-431 (2007).
25. Zhang X, Li L, Wei D, Yap Y, Chen F. Moving cancer diagnostics from bench to bedside. Trends. Biotechnol. 25, 166-173 (2004).
26. Ludwig JA, Weinstein JN. Biomarkers in Cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 5, 845-856 (2005).
27. Becker KF, Metzger V, Hipp S, Höfler H. Clinical proteomics: new trends for protein microarrays. Curr. Med. Chem. 13, 1831-1837. (2006).
28. Ilyin SE, Belkowski SM, Plata-Salamán CR. Biomarker discovery and validation: technologies and integrative approaches. Trends Biotechnol. 22, 411-416 (2004).
29. Riedmaier I, Becker C, Pfaffl W, Meyer HHD. The use of omic technologies for biomarker development to trace functions of anabolic agents. J. Chrom. A. DOI: 10.1016/j. chroma.2009.01.094 (2009) (Epub ahead of print).
30. Minunni M, Scarano S, Mascini M. Affinity-based biosensors as promising tools for gene doping detection. Trends Biotechnol. 26, 236-243 (2008).
31. The International Genome Consortium. Nature 431, 931-945 (2004.).
32. VanGuilder HD, Vrana KE, Freeman WM. Twenty-five years of quantitative PCR for gene expression analysis. BioTechniques 44, 619-626 (2008).
33. Walker MS, Hughes TA. Messenger RNA expression profiling using DNA microarray technology: diagnostic tool, scientific analysis or un-interpretable data? Int. J. Mol. Med. 21, 13-17 (2008).
34. Anderson NL, Polanski M, Pieper R et al. The human plasma proteome. A nonredundant list developed by combination of four separate sources. Mol. Cell Proteomics 3, 311-326 (2004).
35. Mardis ER. The impact of next-generation sequencing technology on genetics. Trend. Genet. 24, 133-141 (2008).
36. Schwenk JM, Gry M, Rimini R, Uhlén M, Nilsson P. Antibody suspension bead arrays within serum proteomics. J. Proteome Res.7, 3168-3179 (2008).
37. Kay RG, Gregory B, Grace PB, Pleasance S. The application of ultra-performance liquid chromatography/tandem MS to the detection and quantitation of apolipoproteins in human serum. Rapid. Commun. Mass. Spectrom. 21, 2585-2593 (2007).
38. Kirsch S, Widart J, Louette J, Focant JF, De Pauw E. Development of an absolute quantification method targeting growth hormone biomarkers using liquid chromatography coupled to isotope dilution MS. J. Chromatogr. A 1153, 300-306 (2007).
39. Mischak A, Apweiler R, Banks RE. Clinical proteomics: a need to define the field and to begin to set adequate standards. Proteomics Clin. App. 1, 148-156 (2007).
40. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell Proteomics 5, 573-588 (2007) 41 O'Farrell PH. High resolution twodimensional electrophoresis of proteins. J. Biol. Chem. 250, 400-421 (1975).
41. Pieper R, Gatlin CL, Makusky AJ. The human serum proteome: display of nearly 3700 chromatographically separated protein spots on two dimensional eletrophoresis gels and identification of 325 distinct proteins. Proteomics 3, 1345-1364 (2003).
42. Tonge R, Shaw J, Middleton B et al. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics 1(3), 377-396 (2001).
43. Keshamouni VG, Michailidis G, Grasso CS et al. Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelialmesenchymal transition reveals a migratory/invasive phenotype. J. Proteome Res. 5, 1143-1154 (2006).
44. Chung L, Clifford D, Buckley M, Baxter RC. Novel biomarkers of human growth hormone action from serum proteomic profiling using protein chip MS. J. Clin. Endocrinol. Metab. 91(2), 671-677 (2006).
45. Hillenkamp F, Karas M. MS of peptides and proteins by matrix-assisted ultraviolet laser desorption/ionization. Methods Enzymol. 193, 280-295 (1990).
46. Anderson NL, Anderson NG. The human plasma proteome: History, character and diagnostic prospects. Mol. Cell. Proteomics 1, 845-867 (2002).
47. Fenn J B, Mann M, Meng CK, Wong SF, Whitehouse CM. Electrospray ionization for MS of large biomolecules. Science 246, 64-71 (1989).
48. Schenk S, Schoenhals GJ, de Souza G, Mann M. A high confidence, manually validated human blood plasma protein reference set. BMC. Med. Genomics. 1, 41 (2008).
49. Nicholson JK, Lindon JC. Systems biology: Metabonomics. Nature 455, 1054-1056 (2008).
50. Lee JW, Devanarayan V, Barrett YC et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 23(2), 312-328 (2006).
51. Goodsaid F, Frueh F. Biomarker qualification pilot process at the US Food and Drug Administration. AAPS. J. 9(1), E105-E108 (2007).
52. Holt RI, Sönksen PH. Growth hormone, IGF-I and insulin and their abuse in sport. Br. J. Pharmacol. 54(3), 542-556 (2008).
53. Sartorio A, Marazzi N, Agosti F et al. Elite volunteer athletes of different sport disciplines may have elevated baseline GH levels divorced from unaltered levels of both IGF-I and GH-dependent bone and collagen markers: a study on-the-field. J. Endocrinol. Invest. 27, 410-415 (2004).
54. Marek U, Geyer H, Opfermann G, Thevis M, Schanzer W. Factors influencing the steroid profile in doping control analysis. J. Mass Spectrom. 43, 877-891 (2008).
55. Velloso CP. Regulation of muscle mass by growth hormone and IGF-I, Br. J.Pharmacol. 154, 557-568 (2008).
56. Baumann G. Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins. Endocr. Rev. 12, 424-449 (1991).
57. Bidlingmaier M, Wu Z, Strasburger CJ. Problems with GH doping in sports. J. Endcrinol. Invest. 26, 924-931 (2003).
58. Armanini D, Faggian D, Scaroni C, Plebani M. Growth hormone and insulin-like growth factor I in a Sydney Olympic gold medallist. Br. J. Sports Med. 36, 148-149 (2002).
59. Liu W, Thomas SG, Asa SL, Gonzalez- Cadavid N, Bhasin S, Ezzat S. Myostatin is a skeletal muscle target of growth hormone anabolic action. J. Clin. Endocrinol. Metab. 88, 5490-5496 (2003).
60. Powrie JK, Bassett EE, Rosen T, Sonksen PH. et al. Detection of growth hormone abuse in sport. Growth Horm. IGF Res. 17, 220-226 (2007).
61. Florini JR, Ewton DZ, Coolican SA, Growth hormone and the insulin-like growth factor system in myogenesis. Endocr. Rev. 17, 481-517 (1996).
62. Bredehoft M, Schanzer W, Thevis M. Quantification of human insulin-like growth factor-1 and qualitative detection of its analogues in plasma using liquid chromatography/electrospray ionisation tandem MS. Rapid Commun. Mass Spectrom. 22, 447-485 (2008).
63. Barton-Davis ER, Shoturma DI, Musaro A, Rosenthal N, Sweeney HL. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc. Natl Acad. Sci. USA 95, 15603-15607 (1998).
64. Barton ER. The ABCs of IGF-I isoforms: impact on muscle hypertrophy and implications for repair. Appl. Physiol. Nutr. Metab. 31(6), 791-797 (2006).
65. Goldspink G, Wessner B, Bachl N. Growth factors, muscle function and doping. Curr. Opin. Pharmacol. 8(3), 352-357 (2008).
66. Cunha SR, Mayo KE. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3′, 5′-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology 143, 4570-4582 (2002).
67. Brown PA, Davis WC, Draghia-Akli R. Immune-enhancing effects of growth hormone-releasing hormone delivered by plasmid injection and electroporation. Mol. Ther. 10, 644-651 (2004).
68. Brown PA, Bodles-Brakhop A, Draghia-Akli R. Plasmid growth hormone releasing hormone therapy in healthy and laminitisafflicted horses-evaluation and pilot study. J. Gene. Med. 10, 564-574 (2008).
69. Draghia-Akli R, Fiorotto ML. A new plasmid-mediated approach to supplement somatotropin production in pigs. J. Anim. Sci. 82(E-Suppl.) E264-E269 (2004).
70. Vestergaard ET, Dall R, Lange KH, Kjaer M, Christiansen JS, Jorgensen JO. The ghrelin response to exercise before and after growth hormone administration. J. Clin. Endocrinol. Metab. 92, 297-303 (2007).
71. McHugh CM, Park RT, Sönksen PH, Holt RI. Challenges in detecting the abuse of growth hormone in sport. Clin. Chem. 1(9), 1587-1593 (2005).
72. Saugy M, Robinson N, Saudan C, Baume N, Avois L, Mangin P. Human growth hormone doping in sport. Br. J. Sports. Med. 40(Suppl. 1), 35-39 (2006).
73. Kicman AT, Miell JP, Teale JD. Serum IGF-I and IGF binding proteins 2 and 3 as potential markers of doping with human GH. Clin. Endocrinol. 47(1), 43-50 (1997).
74. Dall R, Longobardi S, Ehrnborg C. The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. GH-2000 Study Group. J. Clin. Endocrinol. Metab. 85(11), 4193-4200 (2000).
75. Nelson AE, Meinhardt U, Hansen JL. Pharmacodynamics of growth hormone abuse biomarkers and the influence of gender and testosterone: a randomized double-blind placebo-controlled study in young recreational athletes. J. Clin. Endocrinol. Metab. 93(6), 2213-2222 (2008).
76. Nelson AE, Howe CJ, Nguyen TV. Influence of demographic factors and sport type on growth hormone-responsive markers in elite athletes. J. Clin. Endocrinol. Metab. 91(11), 4424-4432 (2006).
77. Erotokritou-Mulligan I, Bassett EE, Cowan DA et al. Influence of ethnicity on IGF-I and procollagen III peptide P-III-P in elite athletes and its ability to detect GH abuse. GH-2004 group. Clin. Endocrinol. 70(1), 161-168 (2009).
78. Healy ML, Dall R, Gibney J et al. Toward the development of a test for growth hormone (GH) abuse: a study of extreme physiological ranges of GH-dependent markers in 813 elite athletes in the postcompetition setting. J. Clin. Endocrinol. Metab. 90, 641-649 (2005).
79. Erotokritou-Mulligan I, Bassett EE, Bartlett C et al. The effect of sports injury on insulin-like growth factor-I and type 3 procollagen: implications for detection of growth hormone abuse in athletes; GH-2004 Group. J. Clin. Endocrinol. Metab. 93(7), 2760-2763 (2008).
80. Holt RIG, Erotokritou-Mulligan I, Ridley SA et al. A determination of the pre-analytical storage conditions for insulin like growth factor-I and type III procollagen peptide. Growth. Horm. IGF Res. 19(1), 43-50 (2009).
81. Nguyen TV, Nelson AE, Howe CJ et al. Within-subject variability and analytic imprecision of insulin like growth factor axis and collagen markers: implications for clinical diagnosis and doping tests. Clin. Chem. 54(8), 1265-1267 (2008).
82. Nelson AE, Ho KK. A robust test for growth hormone doping - present status and future prospects. Asian J. Androl. 10(3), 416-425 (2008).
83. Thakkar R, Butt H, Powrie AN, Holt J, Swaminathan R. Circulating nucleic acids in the assessment of endogenous growth hormone production. Ann. NY Acad. Sci. 1137, 58-65 (2008).
84. Paparini A, Impagnatiello F, Pistilli A et al. Identification of candidate genes and expression profiles, as doping biomarkers. Ann. Ig. 19(4), 303-314 (2007).
85. Boateng J, Kay R, Lancashire L et al. A proteomic approach combining mass spectrometric and bioinformatics analysis for the detection and identification of biomarkers to recombinant human growth hormone administration in humans. Proteomics. Clin. Appl. 3, 912-922 (2009).
86. Boateng J, Lancashire L, Brown P et al. The use of proteomic and bioinformatics techniques for the detection of protein biomarkers following growth hormone administration. Internet J. Genom. Proteom. 2(2), 912-922 (2007).
87. Barton C, Beck P, Kay R, Teale P, Roberts J. Multiplexed LC-MS/MS analysis of horse plasma proteins to study doping in sport. Proteomics 9(11), 3058-3065 (2009).
88. Popot MA, Bobin S, Bonnaire Y, Delahaut PH, Closset J. IGF-I plasma concentrations in non-treated horses and horses administered with methionyl equine somatotropin. Res. Vet. Sci. 7, 167-173 (2001).
89. Noble GK, Houghton E, Roberts CJ et al. Effect of exercise, training, circadian rhythm, age, and sex on insulin-like growth factor-1 in the horse. J. Anim. Sci. 85(1), 163-171 (2007).
90. Bobin S, Popot MA, Bonnaire Y, Tabet JC. Approach to the determination of insulin-likegrowth- factor-I (IGF-I) concentration in plasma by high-performance liquid chromatography-ion trap MS: use of a deconvolution algorithm for the quantification of multiprotonated molecules in electrospray ionization. Analyst 126, 1996-2001 (2001).
91. de Kock SS, Rodgers JP, Swanepoel BC. Growth hormone abuse in the horse: preliminary assessment of a mass spectrometric procedure for IGF-1 identification and quantitation. Rapid Commun. Mass Spectrom. 15(14), 1191-1197 (2001).
92. Popot MA, Woolfitt AR, Garcia P, Tabet JC. Determination of IGF-I in horse plasma by LC electrospray ionisation MS. Anal. Bioanal. Chem. 390(7), 1843-1852 (2008).
93. Bailly-Chouriberry L, Chu-Van E, Pinel G et al. Detection of secondary biomarker of met-eGH as a strategy to screen for somatotrophin misuse in horseracing. Analyst 133(2), 270-276 (2007).
94. Elliott S. Erythropoiesis-stimulating agents and other methods to enhance oxygen transport. Br. J. Pharmacol. 154(3), 529-541 (2008).
95. Damsgaard R, Munch T, Morkeberg J, Mortensen SP, Gonzalez-Alonso J. Effects of blood withdrawl and reinfusion on biomarkers of erythropoiesis in humans: Implications for anti-doping strategies. Haematologica 91, 1006-1008 (2006).
96. Sallet P, Brunet-Guedj E, Mornex R, Baverel G. Study of a new indirect method based on absolute norms of variation to detect autologous blood transfusion. Int. J. Hematol. 88(4), 362-368 (2008).
97. Nelson M, Popp H, Sharpe K, Ashenden MP. Proof of homologous blood transfusion through quantification of blood group antigens. Haematologica 88(11), 1284-1295 (2003).
98. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp. Biol. Med. 228, 1-14 (2003).
99. Segura J, Pascual JA, Gutiérrez-Gallego R. Procedures for monitoring recombinant erythropoietin and analogues in doping control. Anal. Bioanal. Chem. 388(7), 1521-1529 (2007).
100. Diamanti-Kandarakis E, Konstantinopoulos PA, Papailiou J, Kandarakis SA, Andreopoulos A, Sykiotis GP. Erythropoietin abuse and erythropoietin gene doping: detection strategies in the genomic era. Sports Med. 35(10), 831-840 (2005).
101. Parisotto R, Gore CJ, Hahn AG et al. Reticulocyte parameters as potential discriminators of recombinant human erythropoietin abuse in elite athletes. Int J. Sports Med. 21(7), 471-479 (2000).
102. Parisotto R, Wu M, Ashenden MJ et al. Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erythropoiesis. Haematologica 86(2), 128-137 (2001).
103. Ashenden MJ, Hahn AG, Martin DT, Logan P, Parisotto R, Gore CJ. A comparison of the physiological response to simulated altitude exposure and r-HuEpo administration. J. Sports. Sci. 19(11), 831-837 (2001).
104. Sharpe K, Hopkins W, Emslie KR et al. Development of reference ranges in elite athletes for markers of altered erythropoiesis. Haematologica 87(12), 1248-1257 (2002).
105. Gore CJ, Parisotto R, Ashenden MJ et al. Second-generation blood tests to detect erythropoietin abuse by athletes. Haematologica 89(7), 891-892 (2004).
106. Sharpe K, Ashenden MJ, Schumacher YO. A third generation approach to detect erythropoietin abuse in athletes. Haematologica 91(3), 356-363 (2006).
107. UCI 2007 press release announcing plans to take samples for the biological passport in 2008 www.uci.ch/modules/enews/enewsdetails.as p?menuid=mji0nq&id=ntqzoa&langid=1
108. BikeRadar.com reports WADA support for UCI biological passport withdrawn www.bikeradar.com/news/article/ wada-pulls-athlete-passport-project-fromuci- 15344
109. WADA athletes passport www.wada-ama.org/en/dynamic. ch2?pageCategory.id= 754
110. WADA Science and Medicine program www.wada-ama.org/en/dynamic. ch2?pageCategory.id=249
111. Guidelines for blood sample collection www.wada-ama.org/rtecontent/ document/2008-06-GuidelinesBloodSample-unmarked.pdf